A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07777133
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Female Participants

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \[14C\]Navlimetostat (BMS-986504) in healthy female participants

Key Dates

First listed
Aug 20, 2026
Start date
Sep 16, 2026
Status verified
Jul 2026
Primary completion
Dec 5, 2026
Completion
Dec 5, 2026

Study Design

Enrollment
6 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A
  • Experimental: Part B

Primary Outcome Measure

Maximum observed plasma concentration (Cmax) [ Time Frame: Up to 14 days ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Local Institution - 0001MadisonWisconsin53704-2526
Site 0001

Find similar trials in Madison, WI

By research site
Local Institution - 0001· Madison, WI